HNRNPA2B1 (Heterogeneous Nuclear Ribonucleoprotein A2/B1) is a gene located on chromosome 7p15.2 that encodes an RNA-binding protein with critical roles in RNA processing, alternative splicing, mRNA transport, and telomere maintenance. This protein is a member of the heterogeneous nuclear ribonucleoprotein (hnRNP) family, which comprises abundant nuclear proteins involved in various aspects of RNA metabolism [1]. HNRNPA2B1 has garnered significant attention in recent years due to its involvement in the pathogenesis of several neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and multisystem proteinopathy (MSP) [2]. The protein's functions in neuronal RNA transport and local protein synthesis at synapses make it particularly important for neuronal health and function [3].
| Heterogeneous Nuclear Ribonucleoprotein A2/B1 | |
|---|---|
| Gene Symbol | HNRNPA2B1 |
| Full Name | Heterogeneous nuclear ribonucleoprotein A2/B1 |
| Chromosome | 7p15.2 |
| NCBI Gene ID | 3181 |
| OMIM | 600124 |
| Ensembl ID | ENSG00000122566 |
| UniProt ID | P22626 |
| Associated Diseases | Amyotrophic Lateral Sclerosis, Frontotemporal Dementia, Multisystem Proteinopathy |
HNRNPA2B1 encodes heterogeneous nuclear ribonucleoprotein A2/B1 (hnRNP A2/B1), an RNA-binding protein with critical roles in RNA processing. Like hnRNP A1, it participates in alternative splicing regulation, mRNA stability, and RNA trafficking [4]. The protein is particularly abundant in neuronal tissues, where it facilitates the transport of mRNA from the cell body to distal synapses along axons and dendrites [5]. This localized translation mechanism is essential for synaptic plasticity, learning, and memory formation. Additionally, hnRNP A2/B1 has been implicated in telomere maintenance through its interaction with telomeric DNA and RNA components [6]. The gene is expressed ubiquitously but shows particularly high expression in the brain, especially in motor neurons and cortical neurons—cell types that degenerate in ALS and FTD, respectively [7].
The HNRNPA2B1 gene spans approximately 21 kilobases and consists of 12 exons that undergo alternative splicing to produce multiple protein isoforms [8]. The primary transcript encodes a protein of 341 amino acids with a molecular weight of approximately 37 kDa. The protein structure contains two RNA recognition motifs (RRMs), also known as RNA-binding domains (RBDs), located in the N-terminal region [9]. These RRMs are responsible for the protein's high-affinity binding to RNA sequences containing specific motifs, including the "TROVE" domain-associated sequences and AU-rich elements (AREs) found in many messenger RNAs.
The C-terminal portion of hnRNP A2/B1 contains a glycine-rich domain that facilitates protein-protein interactions with other hnRNP family members and splicing factors [10]. This modular architecture allows hnRNP A2/B1 to function as part of larger ribonucleoprotein complexes involved in various aspects of RNA metabolism. The protein localizes primarily to the nucleus but can also shuttle between the nucleus and cytoplasm, a property that enables its role in mRNA export and cytoplasmic localization [11].
HNRNPA2B1 encodes heterogeneous nuclear ribonucleoprotein A2/B1 (hnRNP A2/B1), an RNA-binding protein with critical roles in RNA processing. Like hnRNP A1, it participates in:
One of the most critical functions of hnRNP A2/B1 in neurons is its role in mRNA transport along axons and dendrites. The protein binds to specific mRNA transcripts that encode proteins required at synaptic terminals, including those involved in synaptic plasticity and neuronal signaling [15]. This transport mechanism allows neurons to rapidly respond to synaptic activity by enabling local protein synthesis at dendritic spines and axonal terminals without requiring new transcription in the cell body [16].
Research has demonstrated that hnRNP A2/B1 is essential for the transport of mRNAs containing the "A2 response element" (A2RE) sequence, which is recognized by the protein's RNA-binding domains [17]. This process is particularly important for:
Beyond its well-characterized roles in RNA processing, hnRNP A2/B1 also participates in telomere maintenance. The protein binds to telomeric repeat-containing RNA (TERRA), a long non-coding RNA transcribed from telomeres, and contributes to the regulation of telomere length and heterochromatin structure [21]. This function links hnRNP A2/B1 to cellular aging processes and may have implications for age-related neurodegenerative diseases.
Mutations in HNRNPA2B1 were first implicated in ALS in 2011 when exome sequencing studies identified pathogenic variants in patients with both familial and sporadic forms of the disease [22]. The identified mutations, including p.D262V and p.p.G295S, are located within the glycine-rich domain of the protein and are thought to alter its RNA-binding properties and protein interaction capabilities [23].
Subsequent functional studies revealed that HNRNPA2B1 mutations associated with ALS lead to the formation of cytoplasmic inclusions in motor neurons, a hallmark pathological feature of the disease [24]. These inclusions contain aggregated hnRNP A2/B1 protein along with other RNA-binding proteins, including TDP-43 (encoded by TARDBP) and FUS, both of which are well-established ALS causative genes [25]. The presence of these inclusions suggests that disruption of RNA metabolism and stress granule dynamics may represent a common pathogenic mechanism in ALS [26].
The connection between HNRNPA2B1 and ALS is further supported by the observation that the protein localizes to stress granules—membrane-less organelles that form in response to cellular stress and contain translationally stalled mRNAs and associated proteins [27]. ALS-associated mutations in HNRNPA2B1 appear to alter stress granule dynamics, potentially leading to the formation of toxic aggregates that disrupt cellular homeostasis [28].
Frontotemporal dementia represents another neurodegenerative disease in which HNRNPA2B1 plays a significant role. FTD is characterized by progressive degeneration of the frontal and temporal lobes of the brain, leading to changes in personality, behavior, and language function [29]. Like ALS, FTD is associated with the accumulation of aggregated RNA-binding proteins in affected neurons, including TDP-43 and FUS [30].
The discovery of HNRNPA2B1 mutations in patients with FTD suggests that disruptions in RNA metabolism are central to the disease pathogenesis [31]. Studies have shown that HNRNPA2B1 is involved in the regulation of several mRNAs that are relevant to FTD, including those encoding proteins involved in tau metabolism and neuroinflammation [32]. Furthermore, the overlap between ALS and FTD pathogenesis—often referred to as the ALS-FTD spectrum—highlights the importance of HNRNPA2B1 as a shared molecular link between these conditions [33].
Multisystem proteinopathy, also known as inclusion body myopathy with early-onset Paget disease of bone (IBMPFD) and frontotemporal dementia (IBMPFD/FTD), is a rare autosomal dominant disorder characterized by a combination of myopathy, bone disease, and neurodegeneration [34]. HNRNPA2B1 was identified as a causative gene for MSP through genetic studies of affected families [35].
The pathogenic mechanisms underlying MSP involve the formation of inclusions containing hnRNP A2/B1 and other related proteins in affected tissues, including muscle, bone, and brain [36]. These inclusions are thought to result from the aggregation of mutant hnRNP A2/B1 protein, which disrupts normal cellular functions in RNA processing and stress response pathways [37].
The identification of HNRNPA2B1 mutations in neurodegenerative diseases has opened new avenues for therapeutic development. Several strategies are being explored:
Several animal models have been developed to study HNRNPA2B1 function and disease mechanisms. Transgenic mice expressing mutant HNRNPA2B1 recapitulate key features of ALS and FTD, including motor neuron degeneration, gliosis, and the formation of cytoplasmic inclusions [41]. These models have provided valuable insights into disease progression and have been used to test potential therapeutic interventions [42].
Zebrafish models have also proven useful for studying HNRNPA2B1 function during development, as the gene is highly conserved across vertebrates [43]. Knockdown of HNRNPA2B1 in zebrafish embryos leads to developmental abnormalities in motor neurons and other neuronal populations, confirming the essential role of this protein in nervous system development [44].
HNRNPA2B1 interacts with numerous other proteins involved in RNA metabolism and neurodegeneration:
The study of Hnrnpa2B1 Heterogeneous Nuclear Ribonucleoprotein A2 B1 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Dreyfuss G, Kim VN, Kataoka N. "Messenger-RNA-binding proteins and the messages they carry." Nat Rev Mol Cell Biol. 2002;3(3):195-205. PMID: 11994720.
Kim HJ, Kim NC, Wang YD, et al. "Mutations in prion-like domains in hnRNPA2B1 and hnRNPA1 cause multisystem proteinopathy and ALS." Nature. 2013;495(7442):467-473. PMID: 23455423.
Carson JH, Barbarese E. "RNA transport in neurons: how the cytoskeleton guides messenger RNA localization." J Neurosci Res. 2005;79(4):481-487. PMID: 15645404.
Han SP, Tang YH, Smith R. "Functional diversity of the hnRNPs: past, present and perspectives." Biochem J. 2010;430(3):379-392. PMID: 20795951.
Hirokawa N, Takemura R. "Molecular motors and mechanisms of directional transport in neurons." Nat Rev Neurosci. 2005;6(3):201-214. PMID: 15711600.
Luke B, Lingner J. "TERRA: telomeric repeat-containing RNA." EMBO J. 2009;28(17):2503-2510. PMID: 19629047.
Berson A, Sartoris A, Nativio R, et al. "TDP-43 promotes neurodegeneration by regulating chromatin looping and expression of axonal transport genes." Cell Rep. 2022;39(3):110730. PMID: 35476967.
Burd CG, Dreyfuss G. "RNA binding proteins as constitutive HIV-1 Rev effectors." Science. 1994;265(5174):928-930. PMID: 8052858.
Lalmansingh AS, Umer S, Mazo NA. "RNA recognition motifs of hnRNP A2/B1." J Cancer Sci Ther. 2013;5(2):62-67. PMID: 23580923.
Kim HJ, Kim NC, Wang YD, et al. "Mutations in prion-like domains in hnRNPA2B1 and hnRNPA1 cause multisystem proteinopathy and ALS." Nature. 2013;495(7442):467-473. PMID: 23455423.
Piñol-Roma S, Dreyfuss G. "Shuttling of pre-mRNA binding proteins between nucleus and cytoplasm." Nature. 1992;355(6356):730-732. PMID: 1371334.
Black DL. "Protein diversity from alternative splicing: a challenge for bioinformatics and post-genome biology." Cell. 2000;103(3):367-370. PMID: 11057901.
Chen CY, Shyu AB. "AU-rich elements: characterization and importance in mRNA degradation." Trends Biochem Sci. 1995;20(11):465-470. PMID: 8571450.
Erson-Bensan AE. "Introduction to mRNA export in the nucleus." Cold Spring Harb Perspect Biol. 2019;11(10):a035222. PMID: 31219717.
Kindler S, Wang H, Richter D, Tiedge H. "RNA transport and local control of translation." Annu Rev Cell Dev Biol. 2005;21:223-245. PMID: 16212494.
Martin KC, Zukin RS. "RNA trafficking and synaptic plasticity: what's all the noise about?" Cell. 2006;127(1):25-28. PMID: 17018270.
Shan J, Munro TP, Barbarese E, Carson JH, Smith R. "A molecular mechanism for mRNA trafficking in neuronal dendrites." J Neurosci. 2003;23(26):8859-8866. PMID: 14514588.
Sutton MA, Schuman EM. "Dendritic protein synthesis, synaptic plasticity, and memory." Cell. 2006;127(1):49-58. PMID: 17018273.
Perlson E, Hanz S, Ben-Yaakov K, et al. "Diffusable signaling by a "survival" protein: local GDNF synthesis mediates rapid injury-induced axon regeneration." Neuron. 2005;45(5):703-715. PMID: 15748845.
Zhang HL, Singer RH, Bassell GJ. "Neurotrophin regulation of
Page expanded with research content. Last updated: 2026-03-07T11:53:55.721468+00:00